Dermatology company Intendis opens representative office in Russia

 

• go to german version
• back to news overview

Berlin, February 14, 2006

Intendis GmbH has officially opened its new representative office Intendis Russia at a formal reception in Moscow. The pharmaceutical company dedicated to dermatology is thus continuing its strategy for global growth. ”Opening our new representative office Intendis Russia is yet another step in expanding our business in this important region”, emphasized Prof. Dr. Wolfgang Kehr, CEO of Intendis GmbH.

Intendis Russia evolved from the dermatology division of ZAO Schering Russia, the Russian subsidiary of Schering AG, Berlin. Last year the Schering AG had aggregated its dermatology business in the newly established Intendis GmbH, which commenced business on January 1st, 2005. Vladislav Uvarov will be the General Manager of Intendis Russia. He joins the company from Schering Russia, where he was head of the business units Oncology/Specialized Therapeutics and Diagnostic Imaging, as well as being Head of Sales for Russia.

”We now have a local presence in yet another growth market - which is an important prerequisite for reaching our target of becoming one of the world’s leaders in dermatology”, explained Prof. Dr. Kehr when clarifying the targets of Intendis. The company is represented in all major markets and has subsidiaries in the USA, Japan, Brazil, Mexico, Germany, Italy, Spain, France, Austria, Turkey, Poland and Portugal in addition to the newly established Intendis Russia.

Intendis is a fully integrated pharmaceutical company – dedicated to dermatology. Intendis is focused on the development, manufacturing and marketing of high quality, innovative topical and systemic therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea and fungal skin infections (mycoses). Intendis markets a number of successful brands such as Advantan® and Nerisona® for the treatment of eczema, Travocort® (dermatomycoses), Skinoren® (acne), Finacea® (rosacea) and Psorcutan® and Psorcutan® Beta (psoriasis). The company’s objective is to become a leading partner in the field of dermatology. Intendis GmbH is a wholly-owned subsidiary of Schering AG, Germany.

This press release has been published by Corporate Communication of Intendis GmbH, Berlin, Germany.

Your contact at Corporate Communication:
Intendis GmbH	Sven Winkler +49 30 52 00 75 650 media@intendis.com

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Intendis’ plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Intendis GmbH undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

• Download, 40 KB